Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha.
The aims of this study were to assess the role played by alveolar macrophages, tumor necrosis factor alpha (TNF-alpha), and interleukin-1 alpha (IL-1 alpha) in pulmonary immunity against Pseudomonas aeruginosa in animals that have been immunized via the gut-associated lymphoid tissue. Following intra-Peyer's patch immunization and subsequent intratracheal challenge with live bacteria, significantly enhanced bacterial clearance from the lungs correlated with an increase in bronchoalveolar neutrophils, increased recruitment and phagocytic activity of alveolar macrophages, and accelerated production of TNF-alpha in the bronchoalveolar space, while levels of IL-1 alpha remained low. Administration of recombinant TNF-alpha in physiological concentrations did not affect the proliferation of P. aeruginosa in vitro, but when given intratracheally to rats at the time of infection, recombinant TNF-alpha significantly increased bacterial clearance from the lungs. In these animals, phagocytic activity of bronchoalveolar neutrophils was enhanced, while the recruitment of alveolar macrophages and neutrophils remained unchanged. In acutely infected nonimmune animals, bronchoalveolar concentrations of soluble IL-1 alpha and TNF-alpha increased until the time of death. Levels of prostaglandin E2 and thromboxane B2 were similar in each experimental group. These results indicate that infection in immune animals enhanced both recruitment and phagocytic activity of alveolar macrophages as well as induced an accelerated production of TNF-alpha. In immune challenged animals, this cytokine enhanced the phagocytic activity of neutrophils and improved bacterial clearance from the lung. Levels of soluble IL-1 alpha and TNF-alpha in nonimmune rats increased consistently following infection until the time of death, thus implicating these cytokines in the pathogenesis of acute P. aeruginosa pneumonia.
Buret
A
A
Australian Institute of Mucosal Immunology, Faculty of Medicine, University of Newcastle, Royal Newcastle Hospital, New South Wales, Australia.
Dunkley
M L
ML
Pang
G
G
Clancy
R L
RL
Cripps
A W
AW
D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D016233:Immunotherapy, Active; D007375:Interleukin-1 / Q000096:biosynthesis / Q000494:pharmacology; D007422:Intestines / Q000276:immunology; D008168:Lung / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000648:ultrastructure; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000276:immunology / Q000648:ultrastructure; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010581:Peyer's Patches / Q000276:immunology; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D011552:Pseudomonas Infections / Q000517:prevention & control*; D051381:Rats; D011919:Rats, Inbred Strains; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000494:pharmacology
D001428:Bacterial Vaccines; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha